Randomized, Placebo-Controlled Six-Month Intervention Study of Soy Protein Isolate in Men with Biochemical Recurrence after Radical Prostatectomy: A Pilot Study.


Journal

Nutrition and cancer
ISSN: 1532-7914
Titre abrégé: Nutr Cancer
Pays: United States
ID NLM: 7905040

Informations de publication

Date de publication:
2022
Historique:
pubmed: 26 3 2021
medline: 11 3 2022
entrez: 25 3 2021
Statut: ppublish

Résumé

There is evidence to suggest that soy may be beneficial for prostate cancer patients, but few randomized trials have addressed this. We examined the effect of 6-8 mo soy protein supplementation on prostate specific antigen (PSA) serum levels in men who recurred (PSA > 0.1 ng/ml) within three years of prostatectomy. Sixteen men were randomized to 20 g soy protein (∼24-26/day genistein; ∼40-43/day total isoflavones) or casein placebo. PSA was measured at base line and at 1, 2, 4, and 6-8 mo. Serum genistein levels greatly increased from baseline and cholesterol decreased in the soy group. In both treatment arms PSA increased similarly and PSA doubling times were not different over the 6-8 mo study duration. Two subjects in each group had stable PSA. A literature search for clinical studies of soy, isoflavones, and PSA revealed that supplementation with soy or isoflavones did not affect PSA in virtually all clinical studies identified. Although this study is too small to draw a definitive conclusion on the effect of soy protein on PSA in men with biochemical failure, the null finding in this study is consistent with the results of virtually all reports of soy and soy isoflavones in the literature.

Identifiants

pubmed: 33764851
doi: 10.1080/01635581.2021.1903949
pmc: PMC8756455
mid: NIHMS1758764
doi:

Substances chimiques

Isoflavones 0
Soybean Proteins 0
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-564

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA116195
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA072290
Pays : United States

Références

Int J Cancer. 2005 Feb 20;113(5):835-40
pubmed: 15499622
Urology. 2004 Sep;64(3):510-5
pubmed: 15351581
J Urol. 2005 Sep;174(3):1065-9; discussion 1069-70
pubmed: 16094059
Prostate. 2010 Jul 1;70(10):1127-33
pubmed: 20503397
J Soc Integr Oncol. 2010 Winter;8(1):3-13
pubmed: 20205984
J Urol. 2003 Feb;169(2):507-11
pubmed: 12544298
Nutr Cancer. 2021;73(3):361-368
pubmed: 32347121
Maturitas. 2013 Jun;75(2):125-30
pubmed: 23567264
Urology. 2007 Jun;69(6):1102-6
pubmed: 17572195
Proc Soc Exp Biol Med. 1998 Mar;217(3):263-73
pubmed: 9492334
J Urol. 2009 Nov;182(5):2265-72
pubmed: 19758646
Urology. 2008 Feb;71(2):185-90; discussion 190
pubmed: 18308079
Oncotarget. 2020 Apr 07;11(14):1218-1234
pubmed: 32292572
Oncol Rep. 2006 Dec;16(6):1221-4
pubmed: 17089041
BMC Cancer. 2008 May 11;8:132
pubmed: 18471323
Cancer Sci. 2012 Jan;103(1):125-30
pubmed: 21988617
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1689-96
pubmed: 12496063
Lancet Oncol. 2013 Oct;14(11):1112-1120
pubmed: 24051140
Prostate. 2009 May 15;69(7):719-26
pubmed: 19180569
Nutr Cancer. 2007;59(1):1-7
pubmed: 17927495
Nutr Cancer. 2011;63(6):889-98
pubmed: 21714686
PLoS One. 2013 Jul 12;8(7):e68331
pubmed: 23874588
BJU Int. 2016 Apr;117 Suppl 4:17-34
pubmed: 26898239
Clin Cancer Res. 2003 Aug 15;9(9):3282-7
pubmed: 12960113
Prostate. 2004 May 1;59(2):141-7
pubmed: 15042614
Nutr Cancer. 2006;55(1):1-12
pubmed: 16965235
BJU Int. 2014 May;113(5b):E119-30
pubmed: 24053483
JAMA. 2013 Jul 10;310(2):170-8
pubmed: 23839751
Nutr Cancer. 2010;62(7):996-1000
pubmed: 20924975
Proc Soc Exp Biol Med. 1998 Mar;217(3):274-80
pubmed: 9492335
Nutr Cancer. 2010;62(8):1036-43
pubmed: 21058191
PLoS One. 2013 Oct 22;8(10):e78479
pubmed: 24167630
JAMA. 1999 May 5;281(17):1591-7
pubmed: 10235151
J Urol. 2010 Jan;183(1):345-50
pubmed: 19914662
J Steroid Biochem Mol Biol. 2014 Mar;140:116-32
pubmed: 24373791
Urology. 2004 Feb;63(2):259-63
pubmed: 14972467
Eur J Clin Nutr. 2006 Dec;60(12):1423-9
pubmed: 16775579
Nutr Cancer. 2010;62(2):198-207
pubmed: 20099194
Nutr Cancer. 2004;48(2):160-70
pubmed: 15231450
J Urol. 2001 Jan;165(1):294-300
pubmed: 11125428
Eur J Cancer Prev. 2017 Jan;26(1):71-77
pubmed: 26886237
Nutr Cancer. 2008;60(1):7-13
pubmed: 18444130
Nutr Cancer. 2003;47(2):111-7
pubmed: 15087261
Eur Urol. 2005 Dec;48(6):922-30; discussion 930-1
pubmed: 16263208
Front Pharmacol. 2019 Dec 06;10:1336
pubmed: 31866857
Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):644-8
pubmed: 15066931
Adv Nutr. 2015 Jul 15;6(4):408-19
pubmed: 26178025
Proc Soc Exp Biol Med. 1995 Jan;208(1):18-26
pubmed: 7892289

Auteurs

Maarten C Bosland (MC)

Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA.
Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA.
Department of Urology, New York University School of Medicine, New York, New York, USA.

Joanne Schmoll (J)

Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA.

Hiroko Watanabe (H)

Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA.

Carla Randolph (C)

Department of Environmental Medicine, New York University School of Medicine, New York, New York, USA.

Ikuko Kato (I)

Departments of Oncology and Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH